PT  - JOURNAL ARTICLE
AU  - Alastair Grant
TI  - Apparent reductions in COVID-19 Case Fatality Rates reflect changes in average age of those testing positive
AID  - 10.1101/2020.09.18.20197160
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.09.18.20197160
4099  - http://medrxiv.org/content/early/2020/09/18/2020.09.18.20197160.short
4100  - http://medrxiv.org/content/early/2020/09/18/2020.09.18.20197160.full
AB  - Numbers of COVID-19 infections are rising in many countries, while death and hospitalisation rates remain low. Infection Fatality Rates (IFR) for individual year classes calculated from seroprevalence data and the ages of those dying in England show a very strong log-linear relationship with age, and allow us to predict fatality rates for those testing positive on each day based on their ages. Since the peak of the epidemic, reductions in the ages of cases account for an eight fold fall in fatality rates. Over the same period, increased testing intensity appears to have increased infections detected amongst the most vulnerable by a factor of at least five, and between 15 and 24 fold in the population as a whole. Together these two factors are sufficient to explain the large observed change in the ratio of deaths to reported cases. We can also use these methods to give a more precise early warning system of future increases in mortality rates than raw case numbers. Although case numbers are currently increasing markedly, a continuing reduction in numbers of older individuals being infected means that the predicted increase in mortality rates is much slower.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe research has not received any external research fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The work contains analysis of anonymised data. The use of this, and the text of the paper has been approved by Public Health England, the data ownersAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe anonymised linelist data is available for research purposes from Public Health England (https://www.gov.uk/government/organisations/public-health-england), subject to completion of an Non Disclosure Agreement